Thanks Pat. Hello, to again you with today. pleasure a it's speak
majority the X and progression, is lead represent and critical CAFs, mentioned, activation in one also in metastasis licensed known on strategy will or Pat as as report of first components our solid part clinical role or is initiation, CAFs Phase to targeted data as we radiotherapeutic leader clinical radionuclide ongoing collaboration XXXX, expressed tumor therapeutic fibroblasts the tumor the targeted peptide targeted FAP FAP radiotherapy plan for in of play proteins highly to tumors, expansion discussed program cell candidate most cohorts. which found in PTRT is cancer-associated And Phase be targeting therapy. XB first development. X the compound into for Clovis types. resistance. a of we a program with abundant As in advance in in fibroblast Pharmaceuticals, FAP-XXXX, the our
as based and recent immunosuppressive tumor activity to exhibit such PD-X progression potent blockade. can resistance studies FAP therapies, that demonstrated expressing For example, confirm CAFs have a promote PD-LX and immune
and cancers high quarter, nine across squamous ductal of head FAP sarcoma, both gland, describing and In types associated solid of As observed of as integrated cells that demonstrated non–small FAP most cancer types, tumor cancers. primary, nonclinical salivary of in adenocarcinoma, colon, we metastatic level tumor was the samples expression which tumor highlighted High unknown microenvironment. FAP cell as XX the immunohistochemistry. tumor screened into or last using well squamous we surrounding bladder, expression, these in detected primary have localized analysis types was tumor and lung, independent and predominantly tumor The a also data presented neck mesothelioma, pancreatic expression was high expression fibroblast stage to grade. tumor in FAP
origin, sarcoma and FAP in addition in support planned of investigation expression mesenchymal X CAF data of expansion multiple cancers in tumor types the was mesothelioma the to observed FAP-XXXX in tumor including addition, cohorts in LuMIERE. In These cells Phase population. of
few Additional the presentations of nonclinical anticipated meetings nuclearmedicine data next quarters. medical over at oncology and
a therapeutic in grows pleased FAP-XXXX first are interest enter be first FAP ongoing field our As FAP targeting with into we target LuMIERE and FAP-XXXX be the as the to peptide-targeted to the in increases on monotherapy larger, study. development focused in clinic. we the to radionuclide are mover position Clinically,
number of pre-clinically are FAP-XXXX combinations. However, evaluating drug we a
agents as FAP CAS in immune-based priority. PD-X expressing will these the mediating combinations be such of with Given and therapies, a to PD-LX blockade, role resistance
PD-X evaluating tumor in models. and the of monoclonal in syngeneic antibody nonclinical studies, are efficacy mechanism and action We mouse a of FAP-XXXX
point publications it's immune damage die. will non-clinical is If regular via multiple with number check makes radiotherapy to In the repaired, damage combination to data this induced eventually inhibition an sense supporting PARP [indiscernible] in radiation pairing targeted there support therapy for cell PARP efficacy inhibitors not radioactive are and by combination efficacies. When agents. is the of augments critical [indiscernible] proteins admission. the therapies with damage DNA a inhibitors work targeted This addition causing
We our multiple models. own are with combination group of evaluating pre-clinically inhibitor [indiscernible] with PARP currently tumor FAP-XXXX in
are Lastly, of with radiation care approved a specific to number indications. specific of in standard that sorry, cancer synergize in a – as currently is known agents
For is combination could example, well-known FAP-XXXX. and gemcitabine radiosensitizer utility as a chemotherapy cancer have in used and carcinomas first-line other in with a pancreatic
of We we’ve to combinations field, preclinical educational to created about screen performing reporting To radiotherapy. targeted forward support in are for a emerging throughput look meetings. development. promising upcoming identify FAP-XXXX commitment combination radiations this to of results materials the oncology scientific of We approved this work high our currently drugs
first and video these microsite development introductory targeted Clovis more, in To that FAP-XXXX are radiotherapy targeted materials please an The radionuclide learn a about provide of targetedradiotherapy.com. more program. information visit
which three And we to pharmaceuticals Lastly, have turn collaborating to to update. rights. on we radio the new a clinical three targets additional a over targeted at global that, are Rolfe development, call therapeutic Lindsey for I'll directed with now with program discovery
